Cargando…
Long-Term Weight Change after Initiating Second-Generation Antidepressants
(1) Objective: To examine the relationship between the choice of second-generation antidepressant drug treatment and long-term weight change; (2) Methods: We conducted a retrospective cohort study to investigate the relationship between choice of antidepressant medication and weight change at two ye...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4850471/ https://www.ncbi.nlm.nih.gov/pubmed/27089374 http://dx.doi.org/10.3390/jcm5040048 |
_version_ | 1782429670265847808 |
---|---|
author | Arterburn, David Sofer, Tamar Boudreau, Denise M. Bogart, Andy Westbrook, Emily O. Theis, Mary Kay Simon, Greg Haneuse, Sebastien |
author_facet | Arterburn, David Sofer, Tamar Boudreau, Denise M. Bogart, Andy Westbrook, Emily O. Theis, Mary Kay Simon, Greg Haneuse, Sebastien |
author_sort | Arterburn, David |
collection | PubMed |
description | (1) Objective: To examine the relationship between the choice of second-generation antidepressant drug treatment and long-term weight change; (2) Methods: We conducted a retrospective cohort study to investigate the relationship between choice of antidepressant medication and weight change at two years among adult patients with a new antidepressant treatment episode between January, 2006 and October, 2009 in a large health system in Washington State. Medication use, encounters, diagnoses, height, and weight were collected from electronic databases. We modeled change in weight and BMI at two years after initiation of treatment using inverse probability weighted linear regression models that adjusted for potential confounders. Fluoxetine was the reference treatment; (3) Results: In intent-to-treat analyses, non-smokers who initiated bupropion treatment on average lost 7.1 lbs compared to fluoxetine users who were non-smokers (95% CI: −11.3, −2.8; p-value < 0.01); smokers who initiated bupropion treatment gained on average 2.2 lbs compared to fluoxetine users who were smokers (95% CI: −2.3, 6.8; p-value = 0.33). Changes in weight associated with all other antidepressant medications were not significantly different than fluoxetine, except for sertraline users, who gained an average of 5.9 lbs compared to fluoxetine users (95% CI: 0.8, 10.9; p-value = 0.02); (4) Conclusion: Antidepressant drug therapy is significantly associated with long-term weight change at two years. Bupropion may be considered as the first-line drug of choice for overweight and obese patients unless there are other existing contraindications. |
format | Online Article Text |
id | pubmed-4850471 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-48504712016-05-03 Long-Term Weight Change after Initiating Second-Generation Antidepressants Arterburn, David Sofer, Tamar Boudreau, Denise M. Bogart, Andy Westbrook, Emily O. Theis, Mary Kay Simon, Greg Haneuse, Sebastien J Clin Med Article (1) Objective: To examine the relationship between the choice of second-generation antidepressant drug treatment and long-term weight change; (2) Methods: We conducted a retrospective cohort study to investigate the relationship between choice of antidepressant medication and weight change at two years among adult patients with a new antidepressant treatment episode between January, 2006 and October, 2009 in a large health system in Washington State. Medication use, encounters, diagnoses, height, and weight were collected from electronic databases. We modeled change in weight and BMI at two years after initiation of treatment using inverse probability weighted linear regression models that adjusted for potential confounders. Fluoxetine was the reference treatment; (3) Results: In intent-to-treat analyses, non-smokers who initiated bupropion treatment on average lost 7.1 lbs compared to fluoxetine users who were non-smokers (95% CI: −11.3, −2.8; p-value < 0.01); smokers who initiated bupropion treatment gained on average 2.2 lbs compared to fluoxetine users who were smokers (95% CI: −2.3, 6.8; p-value = 0.33). Changes in weight associated with all other antidepressant medications were not significantly different than fluoxetine, except for sertraline users, who gained an average of 5.9 lbs compared to fluoxetine users (95% CI: 0.8, 10.9; p-value = 0.02); (4) Conclusion: Antidepressant drug therapy is significantly associated with long-term weight change at two years. Bupropion may be considered as the first-line drug of choice for overweight and obese patients unless there are other existing contraindications. MDPI 2016-04-13 /pmc/articles/PMC4850471/ /pubmed/27089374 http://dx.doi.org/10.3390/jcm5040048 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons by Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Arterburn, David Sofer, Tamar Boudreau, Denise M. Bogart, Andy Westbrook, Emily O. Theis, Mary Kay Simon, Greg Haneuse, Sebastien Long-Term Weight Change after Initiating Second-Generation Antidepressants |
title | Long-Term Weight Change after Initiating Second-Generation Antidepressants |
title_full | Long-Term Weight Change after Initiating Second-Generation Antidepressants |
title_fullStr | Long-Term Weight Change after Initiating Second-Generation Antidepressants |
title_full_unstemmed | Long-Term Weight Change after Initiating Second-Generation Antidepressants |
title_short | Long-Term Weight Change after Initiating Second-Generation Antidepressants |
title_sort | long-term weight change after initiating second-generation antidepressants |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4850471/ https://www.ncbi.nlm.nih.gov/pubmed/27089374 http://dx.doi.org/10.3390/jcm5040048 |
work_keys_str_mv | AT arterburndavid longtermweightchangeafterinitiatingsecondgenerationantidepressants AT sofertamar longtermweightchangeafterinitiatingsecondgenerationantidepressants AT boudreaudenisem longtermweightchangeafterinitiatingsecondgenerationantidepressants AT bogartandy longtermweightchangeafterinitiatingsecondgenerationantidepressants AT westbrookemilyo longtermweightchangeafterinitiatingsecondgenerationantidepressants AT theismarykay longtermweightchangeafterinitiatingsecondgenerationantidepressants AT simongreg longtermweightchangeafterinitiatingsecondgenerationantidepressants AT haneusesebastien longtermweightchangeafterinitiatingsecondgenerationantidepressants |